Mark Bartholomä - Concepedia

Author

Mark Bartholomä

Also Known As

Bartholoma, M., Bartholoma, M.D., Bartholomä, Mark D., Bartholomä, Mark, Bartholomä, Mark D, Bartholomä, Mark D., M Bartholomä, M. Bartholomä, Mark BARTHOLOMÄ, Mark Bartholomä

166

Publications

Citations

H-Index

Concepts

All Affiliations

Saarland University University of Freiburg University Medical Center Freiburg German Cancer Research Center Syracuse University

About

Mark Bartholomä is an author at Saarland University specializing in medicine, engineering, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	497
2	Engineering	10	10	452
3	Health Sciences	5	5	277
4	Natural Sciences	2	2	184
5	Biochemistry	2	2	184

Mark Bartholomä

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Oncogenic JAK2 <sup>V617F</sup> causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms Alessandro Prestipino, Alica Joana Emhardt, Konrad Aumann, Science Translational Medicine	2018	218
225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience Fadi Khreish, Niklas Ebert, Martin Ries, European Journal of Nuclear Medicine and Molecular Imaging UrologyGenitourinary CancerMedicineCancer Management225Ac-psma-617/177lu-psma-617 Tandem Therapy	2019	207
High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers Michael Hettich, Friederike Braun, Mark Bartholomä, Theranostics	2016	191
Complex Formation of ICL670 and Related Ligands with Fe<sup>III</sup> and Fe<sup>II</sup> S. Steinhauser, Uwe Heinz, Mark Bartholomä, European Journal of Inorganic Chemistry Inorganic ChemistryChemical EngineeringFe IiiEngineeringBiochemistry	2004	169
Recent developments in the design of bifunctional chelators for metal-based radiopharmaceuticals used in Positron Emission Tomography Mark Bartholomä Inorganica Chimica Acta Positron Emission TomographyRecent DevelopmentsEngineeringImaging AgentRadioanalytical Chemistry	2012	127
Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist <sup>68</sup>Ga-RM2 And PET C. Stoykow, Thalia Erbes, Helmut R. Maëcke, Theranostics	2016	116
177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study) Fadi Khreish, Zaidoon Ghazal, Robert J. Marlowe, European Journal of Nuclear Medicine and Molecular Imaging	2021	83
Molecular imaging and biochemical response assessment after a single cycle of [<sup>225</sup>Ac]Ac-PSMA-617/[<sup>177</sup>Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [<sup>177</sup>Lu]Lu-PSMA-617 monotherapy Florian Rosar, Fabian Hau, Mark Bartholomä, Theranostics	2021	80
Targeting the Cubilin Receptor through the Vitamin B<sub>12</sub> Uptake Pathway: Cytotoxicity and Mechanistic Insight through Fluorescent Re(I) Delivery Nerissa T. Viola, Amy E. Rabideau, Mark Bartholomä, Journal of Medicinal Chemistry	2009	76
Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: Preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET/CT Gesche Wieser, Ilinca Popp, Hans Christian Rischke, European Journal of Nuclear Medicine and Molecular Imaging Positron Emission TomographyUrologyMedical ImagingGastrin-releasing Peptide ReceptorMedicine	2017	57

Page 1